Sanofi/Regeneron's sarilumab hits first PhIII arthritis endpoints
This article was originally published in Scrip
Executive Summary
Sarilumab, Sanofi and Regeneron Pharmaceuticals' experimental antibody drug, has met its three primary endpoints in a Phase III trial in rheumatoid arthritis. The product was shown to be effective in patients with active, moderate to severe disease, who had responded inadequately to methotrexate therapy, both improving disease signs and symptoms and inhibiting the progression of joint damage.